Fulgent Genetics Inc
$ 18.78
-0.79%
11 Jun - close price
- Market Cap 539,328,000 USD
- Current Price $ 18.78
- High / Low $ 19.03 / 18.67
- Stock P/E N/A
- Book Value 36.39
- EPS -2.40
- Next Earning Report 2026-07-31
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.05 %
- ROE -0.07 %
- 52 Week High 31.04
- 52 Week Low 13.46
About
Fulgent Genetics, Inc., provides COVID-19 testing and genetic testing services to physicians with clinically actionable diagnostic information. The company is headquartered in Temple City, California.
Analyst Target Price
$18.50
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-01 | 2026-02-27 | 2025-11-07 | 2025-08-01 | 2025-05-02 | 2025-02-28 | 2024-11-08 | 2024-08-02 | 2024-05-03 | 2024-02-28 | 2023-11-03 | 2023-08-04 |
| Reported EPS | -0.36 | 0.16 | 0.14 | 0.07 | 0.04 | 0.04 | 0.31 | 0.15 | -0.01 | 0.28 | -0.39 | -0.08 |
| Estimated EPS | -0.35 | -0.0602 | -0.22 | -0.18 | -0.18 | -0.369 | -0.15 | -0.3 | -0.32 | -0.29 | -0.32 | -0.33 |
| Surprise | -0.01 | 0.2202 | 0.36 | 0.25 | 0.22 | 0.409 | 0.46 | 0.45 | 0.31 | 0.57 | -0.07 | 0.25 |
| Surprise Percentage | -2.8571% | 365.7807% | 163.6364% | 138.8889% | 122.2222% | 110.8401% | 306.6667% | 150% | 96.875% | 196.5517% | -21.875% | 75.7576% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-07-31 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.44 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: FLGT
2026-06-04 06:09:15
Fulgent Genetics Inc. (FLGT) is showing strong near and mid-term sentiment but a weak long-term outlook, with an exceptional risk-reward short setup targeting a significant downside. AI models have generated distinct trading strategies, including position trading, momentum breakout, and risk hedging, with specific entry, target, and stop-loss zones. The analysis indicates a mid-channel oscillation pattern and highlights current signals for positioning and risk parameters.
2026-06-03 21:40:18
Fulgent Genetics Chief Scientific Officer Gao Hanlin sold 1,688 shares of company stock worth $30,190 to cover tax withholding obligations. Following the sale, Hanlin still holds 990,374 shares. The company recently reported lower-than-expected Q1 2026 earnings and revenue but holds more cash than debt and is developing new services like FoundationOne PGx and advancing a Phase 2 clinical trial for a cancer drug.
2026-06-03 21:39:51
Fulgent Genetics (FLGT) CFO Paul Kim reported a routine share disposition where 2,087 shares of common stock were withheld at $18.09 per share to cover tax obligations from the vesting of restricted stock units. This was a non-market event related to compensation, not an open-market sale. After this transaction, Kim directly holds 362,545 shares of Fulgent Genetics common stock.
2026-06-03 21:39:51
Fulgent Genetics President and COO Jian Xie sold 2,146 shares of common stock on June 2, 2026, at a weighted-average price of $17.8855 per share. This sale was conducted to cover tax withholding obligations associated with the vesting of restricted stock units granted in February 2025. Following the transaction, Xie directly holds 367,605 shares and indirectly holds an additional 220,816 shares through The Hsieh Family Dynasty Trust.
2026-06-03 21:39:51
Fulgent Genetics' Chief Scientific Officer, Hanlin Gao, sold 1,688 shares of common stock at a weighted-average price of $17.8855 per share. This sale was conducted to satisfy tax withholding obligations arising from the vesting of previously granted restricted stock units. Following this transaction, Gao directly holds 990,374 shares of Fulgent Genetics common stock.
2026-06-03 01:09:15
Fulgent Genetics (NASDAQ: FLGT) filed a Form 144 indicating the intended resale of 45,304 restricted common shares that vested on February 25, 2025. The filing also disclosed a prior sale of 1,201 shares on May 27, 2026, by Jian Xie, with Morgan Stanley Smith Barney LLC listed as the broker. This administrative filing provides procedural disclosures required for restricted stock sales.
